Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Idera Pharmaceuticals
Biotech
Idera buys rare-disease-focused Aceragen in all-stock deal
What caught Idera’s attention was Aceragen’s lead assets, including ACG-701, which is set to enter phase 2 trials later this year.
James Waldron
Sep 29, 2022 7:30am
Idera's only asset flounders as biotech, AbbVie end enrollment
Dec 15, 2021 11:15am
Idera's TLR9 drug flunks melanoma phase 3, tanking stock
Mar 19, 2021 8:45am
Idera’s TLR9-Yervoy combo works in PD-1-refractory melanoma
Dec 14, 2018 10:48am
BioCryst stockholders call off merger with Idera Pharmaceuticals
Jul 11, 2018 10:20am
Idera's dermatomyositis drug flops in phase 2
Jun 12, 2018 10:09am
